Ultrashort Antimicrobial Peptide-Antibiotic Conjugate: A New Weapon Against Resistance
Novel conjugate combining an ultrashort antimicrobial peptide with levofloxacin showed enhanced antibacterial activity against resistant strains through dual-mechanism killing.
Quick Facts
What This Study Found
Novel conjugate combining an ultrashort antimicrobial peptide with levofloxacin showed enhanced antibacterial activity against resistant strains through dual-mechanism killing.
Key Numbers
Five-amino-acid peptide (UP5) with alternating arginine and biphenylalanine units conjugated to levofloxacin. Tested against multidrug and levofloxacin-resistant isolates.
How They Did This
Study methodology detailed in the full publication.
Why This Research Matters
Relevant to the expanding applications of peptide-based therapies in medicine.
The Bigger Picture
Contributes to the growing body of evidence for peptide therapeutics across medical specialties.
What This Study Doesn't Tell Us
Limitations discussed in the full publication.
Questions This Raises
- ?What are the long-term implications?
- ?How do results compare to existing evidence?
- ?What research is needed next?
Trust & Context
- Key Stat:
- Key finding Novel conjugate combining an ultrashort antimicrobial peptide with levofloxacin showed enhanced anti
- Evidence Grade:
- Evidence level based on study design.
- Study Age:
- Published in 2025.
- Original Title:
- Development of a novel ultrashort antimicrobial peptide-levofloxacin conjugate with enhanced synergistic activity against multidrug and levofloxacin-resistant bacterial isolates.
- Published In:
- Research in pharmaceutical sciences, 20(6), 777-788 (2025)
- Authors:
- Almaaytah, Ammar(3), Alrashdan, Aseel, Sabi, Salsabeel H(2)
- Database ID:
- RPEP-09877
Evidence Hierarchy
Frequently Asked Questions
What does this mean for patients?
Novel conjugate combining an ultrashort antimicrobial peptide with levofloxacin showed enhanced antibacterial activity against resistant strains through dual-mechanism killing.
How reliable is this?
Consult the full publication and healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09877APA
Almaaytah, Ammar; Alrashdan, Aseel; Sabi, Salsabeel H. (2025). Development of a novel ultrashort antimicrobial peptide-levofloxacin conjugate with enhanced synergistic activity against multidrug and levofloxacin-resistant bacterial isolates.. Research in pharmaceutical sciences, 20(6), 777-788. https://doi.org/10.4103/RPS.RPS_178_24
MLA
Almaaytah, Ammar, et al. "Development of a novel ultrashort antimicrobial peptide-levofloxacin conjugate with enhanced synergistic activity against multidrug and levofloxacin-resistant bacterial isolates.." Research in pharmaceutical sciences, 2025. https://doi.org/10.4103/RPS.RPS_178_24
RethinkPeptides
RethinkPeptides Research Database. "Development of a novel ultrashort antimicrobial peptide-levo..." RPEP-09877. Retrieved from https://rethinkpeptides.com/research/almaaytah-2025-development-of-a-novel
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.